Forget Casgevy: CRISPR Therapeutics’ Heart-Disease Data Could Matter More
CRISPR Therapeutics (NASDAQ: CRSP) has a major claim to fame. It developed a medicine called Casgevy, which in 2023 became the first approved therapy to use the Nobel Prize-winning CRISPR gene-editing technique. Casgevy is currently CRISPR Therapeutics’ only approved medicine, and it shares the rights to it with Vertex Pharmaceuticals (NASDAQ: VRTX). This therapy is important to CRISPR Therapeutics’ prospects, but the company arguably has even more critical catalysts on the horizon.
Notably, the mid-cap biotech has several promising candidates in the pipeline that could make significant progress over the next few years. Let’s discuss one of them: CTX310. Here’s why this investigational medicine is, perhaps, even more important to CRISPR Therapeutics’ future.
Image source: The Motley Fool.
Source: www.fool.com — article syndicated from the publisher’s feed; all rights remain with the original publisher.